Amcenestrant - Sanofi
Alternative Names: SAR 439859; SERD '859Latest Information Update: 31 Oct 2022
At a glance
- Originator Sanofi
- Developer Alliance Foundation Trials; Breast International Group; European Organisation for Research and Treatment of Cancer; Sanofi
- Class 2 ring heterocyclic compounds; Antineoplastics; Carboxylic acids; Chlorobenzenes; Ethers; Fluorinated hydrocarbons; Phenols; Pyrrolidines; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 19 Oct 2022 Adverse events and efficacy data from a phase II AMEERA-3 trial in Breast cancer presented at the 47th European Society for Medical Oncology Congress (ESMO 2022)
- 23 Aug 2022 Discontinued - Phase-I for Breast cancer (In the elderly, In volunteers, In adults) in Germany (PO)
- 23 Aug 2022 Discontinued - Phase-III for Breast cancer (Combination therapy, Early-stage disease, Adjuvant therapy) in Japan (PO)